January 12, 2022
# Scientific MSPC | The drug OCREVUS reduced relapses and delayed the progression of disability in relapsing multiple sclerosis, as evidenced in several studies, where this drug was compared with REBIF.
Participants in the studies with relapsed MS fared better with this treatment.
#MSP: The most relevant for doctors, patients and health professionals. #Pioneers